Trial: 202103114

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

Phase

II (Cancer Control)

Principal Investigator

Waqar, Saiama

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov